What Is It, and Why Does It Matter? Capvaxive is a 21-valent pneumococcal conjugate vaccine (PCV21). It trains your immune system to recognize 21 types of Streptococcus pneumoniae, a germ that can ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE ® ...

The aim of the study is to understand if the combination of the vaccines is safe, and the immune response after adding the ...

Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Pfizer Inc. (PFE) is running a Phase 3 trial titled “A Phase 3, Randomized Double-Blind Trial to ...

Pfizer (PFE) on Wednesday announced that it has begun a Phase 3 trial for its 25-valent pneumococcal vaccine, PF-07872412 (25vPnC), for infants after the shot outperformed its pneumococcal 20-valent ...

With recent changes from the Centers for Disease Control and Prevention regarding which routine vaccines that children and teens should get, it's only natural that there might be some confusion.

"Young children have the greatest burden of severe disease, so choosing the right vaccine to protect against the main serotypes circulating in the community is crucial." — Tony Walls, MD, Department ...

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter GlaxoSmithKline (GSK) has completed a Phase 1 trial titled “A Phase 1, Observer-Blind, ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...